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Abstract
Background:  Studies of gene expression in post mortem human brain can contribute to
understanding of the pathophysiology of neurodegenerative diseases, including Alzheimer's disease
(AD), Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Quantitative real-time PCR
(RT qPCR) is often used to analyse gene expression. The validity of results obtained using RT qPCR
is reliant on accurate data normalization. Reference genes are generally used to normalize RT qPCR
data. Given that expression of some commonly used reference genes is altered in certain
conditions, this study aimed to establish which reference genes were stably expressed in post
mortem brain tissue from individuals with AD, PD or DLB.
Results: The present study investigated the expression stability of 8 candidate reference genes,
(ubiquitin C [UBC], tyrosine-3-monooxygenase [YWHAZ], RNA polymerase II polypeptide [RP II],
hydroxymethylbilane synthase [HMBS], TATA box binding protein [TBP], β-2-microglobulin
[B2M], glyceraldehyde-3-phosphate dehydrogenase [GAPDH], and succinate dehydrogenase
complex-subunit A, [SDHA]) in cerebellum and medial temporal gyrus of 6 AD, 6 PD, 6 DLB
subjects, along with 5 matched controls using RT qPCR (TaqMan® Gene Expression Assays). Gene
expression stability was analysed using geNorm to rank the candidate genes in order of decreasing
stability in each disease group. The optimal number of genes recommended for accurate data
normalization in each disease state was determined by pairwise variation analysis.
Conclusion: This study identified validated sets of mRNAs which would be appropriate for the
normalization of RT qPCR data when studying gene expression in brain tissue of AD, PD, DLB and
control subjects.
Background
The mechanisms underlying certain neurodegenerative
diseases such as Alzheimer's disease (AD), Parkinson's
disease (PD), and dementia with Lewy bodies (DLB)
remain poorly understood. One approach to further the
understanding of such diseases is to study expression pat-
terns of key genes in the affected tissue, human post-mor-
tem brain. Quantitative real-time PCR (RT qPCR) is a fast,
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straightforward and reproducible technique which
negates the need for post-PCR product handling and is
increasingly becoming the method of choice for the accu-
rate profiling of mRNA levels (gene expression) due to its
accuracy, wide dynamic range and sensitivity [1-3]. RT
qPCR enables the investigator to determine the expression
levels of a given set of genes in a range of samples and is
particularly useful when the sample quantity is limited [4-
6].
Despite the many merits of RT qPCR, there are a number
of inherent issues associated with its use, of which identi-
fication of a valid reference for data normalisation
remains the most problematic [1,7]. At present, the most
common method for such normalisation is the use of a
single internal control reference gene – often referred to as
a 'housekeeping gene'. The choice of genes regularly
employed in RT qPCR for this purpose, such as β-actin,
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and 18S rRNA stems from their use in traditional non- or
semi-quantitative methods such as northern blotting.
However, there is strong evidence in the literature to sug-
gest that whilst the expression of some such reference
genes may be constant under certain conditions, in other
conditions they may fluctuate significantly [8-11]. There
have been cases in which commonly accepted reference
genes, such as GAPDH and β-actin, have been shown to
be affected by in vitro experimental conditions [12], as
well as clinical conditions such as asthma, and therefore
may not always be suitable for normalisation [13]. Nor-
malization of data using a non-validated reference gene
may lead to inaccurate results and erroneous conclusions,
and previous studies have reinforced the need to validate
housekeeping genes prior to their use in a study [7,14].
The 'ideal' reference gene for RT qPCR would be one
whose mRNA is consistently expressed at the same level in
all samples under investigation, regardless of tissue type,
disease state, medication or experimental conditions and
would have expression levels comparable to that of the
target [10]. However, the 'ideal' reference gene has yet to
be discovered, and more than likely does not exist.
In addition to geNorm, several other Microsoft Excel
based applications, such as NormFinder [15] and Best-
Keeper [16], are now available to asses the degree of vari-
ation in candidate reference genes. In geNorm, rather than
using a single reference gene, Vandesompele et al. [17]
proposed the use of more than one validated reference
gene for data normalization. Use of two or more properly
validated reference genes can provide improved resolu-
tion [18], and geNorm takes into account any differences
in PCR reaction efficiencies, unlike earlier studies using
the 2-ΔΔCt method [19], which assumes all efficiencies to
be at, or close to, 100%. To identify appropriate reference
genes for a particular tissue and disease state, it is neces-
sary to examine expression profiles of candidate genes to
identify the most stable. Other studies have investigated
this in post mortem brain tissue samples from individuals
with other causes of death [20-22], and there is at least
one study of reference gene expression in post mortem
brain tissue from individuals with neurodegenerative con-
ditions [23], but no previous investigations of post mor-
tem brain tissue from individuals with AD, PD or DLB
have used geNorm to identify the most stable reference
genes, to our knowledge.
The issue of RNA quality is often raised in the context of
gene expression analysis in human post mortem brain, as
RNA integrity can be affected by pre- and post mortem fac-
tors [24]. An objective RNA integrity number (RIN, where
1 is poor, and 10 best) can now be determined using an
Agilent Bioanalyser, replacing previous gel-based meth-
ods, and providing a better predictor of RNA quality [25].
The degree of RNA integrity required varies depending on
the downstream RNA analysis method, and needs to be
determined empirically for each application. This is an
active area of research, and a recent study [26] analysed
the influence of RNA sample RIN (1–10) on apparent
gene expression levels and PCR efficiency, using RT qPCR.
The study demonstrated that RT qPCR assay data based on
short amplicons (70–250 bp) were independent of RIN.
Longer amplicons (> 400 bp) were affected by RIN, and
for these, it was recommended that samples with a RIN
value of 5 or above were preferable [26]. The authors dem-
onstrated that the impact of RNA integrity on relative
quantification of gene expression could be minimized by
normalization using validated internal reference genes,
and by correcting for PCR efficiency [26].
In the present study, we examined the expression of can-
didate reference genes (Table 1) in the cerebellum and
medial temporal gyrus from individuals with AD, PD,
DLB, and controls, in order to provide a set of validated
reference genes for use in the study of gene expression pat-
terns in these neurodegenerative diseases.
Results
RNA Integrity Analysis
Total RNA preparations were analysed using an Agilent
2100 Bioanalyzer (Agilent Technologies). Mean RIN val-
ues (± S.D.) were 3.2 ± 1.5 (range from 2.0 to 6.9), indi-
cating that RNA degradation had occurred in some of
these post mortem brain tissue samples, despite the efforts
taken to minimise this (see Methods). RINs of repeat
preparations of RNA from the same tissue block showed a
high degree of correlation with previous RNA samples
(linear regression analysis, r2 = 0.66, p = 0.001) indicating
that this was a feature of the tissue, rather than the RNA
preparation method. We carried out some further analysisBMC Molecular Biology 2008, 9:46 http://www.biomedcentral.com/1471-2199/9/46
Page 3 of 11
(page number not for citation purposes)
of this issue. Firstly, we found no correlation between
RNA integrity (RIN) and disease progression, as indicated
by sample Braak score (Spearman rank correlation). In
addition, we found no significant correlations between
RIN, and PMD or pH (Spearman rank correlation). We
investigated whether any relationships existed between
RIN, and gene expression data, expressed as the normal-
ised relative quantity (Q) of each gene. There were no sig-
nificant correlations between sample RIN and Q for any of
the genes studied, in either cerebellum or medial tempo-
ral gyrus (Spearman rank correlation, p > 0.05 for all cor-
relations). This indicated that the measures taken to
minimise the impact of partial RNA degradation on the
RT-qPCR assays (see below, in brief: inclusion of random
nonomer primers in RT reactions in addition to oligo dT,
and use of RT qPCR primer pairs designed to produce
amplicons of 127 bp or less) had been successful. This is
in agreement with the Fleige&Pfaffl study, where RT qPCR
assays based on amplicons of 250 bp and less were inde-
pendent of RNA quality [26].
PCR Efficiency
cDNA was prepared from cerebellum and medial tempo-
ral gyrus of AD, PD, DLB, and matched control subjects.
Using 10-fold serial dilutions of pooled cDNA, the PCR
reaction efficiency of each gene assay, as listed in Table 1,
was determined from the respective cDNA v Ct efficiency
plots (see Additional File 1). The efficiency plots for each
of the candidate genes were found to have r2 ≥ 0.997. All
gene assays were found to have efficiencies ≥ 92%, with
several being ≥ 99% (Table 2).
Expression data analysis
mRNA levels of UBC, YWHAZ, RP II, HMBS, TBP, B2M,
GAPDH and SDHA were determined in cerebellum and
medial temporal gyrus from individuals with AD, PD,
DLB and matched controls. The median, 25th and 75th per-
centiles, and range of Ct values for each gene in each brain
region across differing disease states are presented in Fig-
ure 1, illustrating the variation in expression levels
between the different subject groups and brain regions.
The standard deviation of gene-specific replicate samples
was used to calculate the mean intra-run variation. The
intra-run variation (CV) for each candidate reference gene
ranged from 0.22% for UBC to 0.49% for GAPDH with a
mean CV for all genes of 0.4%.
In order to quantify the degree of variation in candidate
reference gene, and hence obtain a measure of the most
stably expressed genes, the geNorm algorithm [17] was
employed to analyse the raw expression data for our can-
didate genes. Using geNorm, it was possible to carry out
sequential elimination of the least stable gene in any
given experimental group, thus resulting in the exclusion
of all but the two most stable genes in each case. In future
gene expression studies we intend to measure levels of tar-
get genes in differing neurodegenerative disease subjects
compared to control subjects; therefore it was necessary to
ascertain the stability of the candidate genes across panels
of grouped disease and control subjects, rather than in dis-
ease-specific subjects alone. geNorm analysis was per-
formed on the gene expression data from the cerebellum
and medial temporal gyrus of the following three group-
ings: controls and AD subjects, controls and PD subjects,
and controls and DLB subjects. geNorm analysis of the
candidate genes in each of the above groupings, in each
Table 1: Candidate reference genes
Gene 
Symbol
Gene Name Cellular Function TaqMan Assay Number* Context Sequence
SDHA Succinate dehydrogenase complex, subunit A dehydrogenase Hs00417200_m1 CGCCGCCGTGGTCGAGCTAGAAAAT
UBC Ubiquitin C ubiquitination Hs00824723_m1 CTGTGATCGTCACTTGACAATGCAG
YWHAZ Tyrosine-3-monooxygenase signal transduction Hs00237047_m1 GGAGATAAAAAGAACATCCAGTCAT
RP II RNA polymerase II polypeptide J DNA-directed RNA polymerase Hs00196523_m1 AACATCATTAAATCACAACTCCTAA
HMBS Hydroxymethylbilane synthase deaminase Hs00609297_m1 GCGGCTGCAACGGCGGAAGAAAACA
TBP TATA box binding protein transcription factor Hs99999910_m1 TGGGTTTTCCAGCTAAGTTCTTGGA
B2M β-2-microglobulin histocompatibility complex antigen Hs99999907_m1 AAGTGGGATCGAGACATGTAAGCAG
GAPDH Glyceraldehyde-3-phosphate dehydrogenase dehydrogenase Hs99999905_m1 GGCGCCTGGTCACCAGGGCTGCTTT
* 'm1' suffix denotes cDNA specific assays.
The 'context sequence' is the nucleotide sequence surrounding the region to which the probe binds. The primer and probe sequences for the TaqMan assays are not available. 
Detailed information for each TaqMan assay is freely available on http://www.appliedbiosystems.com
Table 2: Efficiency data for candidate reference genes
Gene Symbol Slope R2 Efficiency
UBC -3.332 0.996 99%
YWHAZ -3.345 0.998 99%
RP II -3.412 0.9995 96%
HMBS -3.294 0.997 100%
TBP -3.317 0.9944 100%
B2M -3.452 0.9992 95%
GAPDH -3.519 0.999 92%
SDHA -3.456 0.9985 95%
Ct values obtained from 10-fold serial dilutions of pooled cDNA (from 
×10 dilution to ×100000 dilution) were plotted against dilution 
factors. The reaction efficiency was calculated using the equation E = 
10(-1/slope) where 'E' is the efficiency and 'slope' is the gradient of the 
best fit line.BMC Molecular Biology 2008, 9:46 http://www.biomedcentral.com/1471-2199/9/46
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brain region; identified sets of genes appropriate for nor-
malization of data in each group.
To determine the optimal number of genes required for
geometric mean normalization, geNorm calculates the
pairwise variation (Vn/Vn+1) between sequential normali-
zation factors (NF) (NFn and NFn+1). A large variation
indicates that the gene included at that stage has a signifi-
cant effect and should therefore be included for normali-
zation. In the original publication describing geNorm
[17] a threshold of 0.15 for the pairwise variation was
established, below which the authors believe the inclu-
sion of additional reference genes is not necessary; there-
fore we also adopted the same threshold as a cut-off for
the inclusion of our references genes.
Analysis of data for the medial temporal gyrus of the con-
trol and AD subjects using geNorm produced a plot indi-
cating the average expression stability of the remaining
candidate reference genes in each round of the analysis
(Figure 2A), ranking the candidate genes from least stable
to the two most stable genes (Table 3A). Evaluation of the
AD and control medial temporal gyrus group revealed a
decrease in the pairwise variation with the inclusion of a
fourth gene (compare V2/3 with V3/4). Although the pair-
wise variation at V3/4 (0.166) does not cross the threshold
of 0.15, it can be seen from the increase in pairwise varia-
tion at V4/5 that the addition of a fifth gene was of no ben-
efit (Figure 2B). Therefore, for data normalisation of this
subject group, it would be appropriate to use UBC, HMBS,
SDHA and YWHAZ as reference genes (denoted by an
asterisk in Table 3A).
RT qPCR cycle threshold value ranges for candidate genes Figure 1
RT qPCR cycle threshold value ranges for candidate genes. Expression data displayed as cycle threshold (Ct) values for 
each candidate reference gene in both cerebellum and medial temporal gyrus in controls, AD, PD and DLB subjects. The line in 
each box indicates the median. The box represents the 25th and 75th percentiles. Whiskers represent the maximum and mini-
mum values.
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Similar analysis of the medial temporal gyrus from con-
trols and PD subjects ranked the candidate genes from the
two most stable (GAPDH and SDHA) to the least stable
(YWHAZ) (Additional File 2B). Use of the pairwise varia-
tion for the determination of the optimal number of con-
trol genes to be included indicated V2/3 = 0.138, below the
threshold of 0.15. Therefore, although the inclusion of a
fourth gene decreases the pairwise variation to 0.113, the
use of three reference genes should be adequate for this
group (Additional File 3B and Table 3A).
In the medial temporal gyrus of the DLB and control
group, B2M and SDHA were found to be the most stable,
with YWHAZ the least (Additional Figure 2C and Table
3A). As in the previous group, V2/3 falls below the thresh-
old of 0.15, therefore the use of three reference genes
(B2M, SDHA and GAPDH) should be sufficient (Addi-
tional File 3C and Table 3A).
The stability of each of the candidate reference genes was
determined in cerebellum tissue of each subject grouping
(as described above for the medial temporal gyrus), with
a different rank order of the candidate reference genes
being found for each group (Additional File 4A, 4B &4C
and Table 3B). Analysis of the pairwise variation with the
inclusion of each additional gene was carried out to deter-
mine the optimal number of reference genes required for
each group (Additional File 5A,B&5C and Table 3B).
Gene expression stability and pairwise variation of the candi- date reference genes using geNorm analysis Figure 2
Gene expression stability and pairwise variation of 
the candidate reference genes using geNorm analy-
sis. A – Expression stability plot showing the average expres-
sion stability (M) for the remaining genes following the 
sequential elimination of the least stable gene at each round. 
Least stable (left) and the two most stable (right). B – Pair-
wise variation analysis to determine the optimal number of 
reference genes for use in RT qPCR data normalization.
Table 3: Ranking of candidate reference genes in order of 
stability
A
MEDIAL TEMPORAL GYRUS
AD + Controls PD + Controls DLB + Controls
*UBC/*HMBS *GAPDH/*SDHA *B2M/*SDHA
*SDHA *HMBS *GAPDH
*YWHAZ TBP TBP
B2M UBC UBC
GAPDH B2M HMBS
RP II RP II RP II
TBP YWHAZ YWHAZ
CEREBELLUM
AD + Controls PD + Controls DLB + Controls
*YWHAZ/*GAPDH *HMBS/*GAPDH *UBC/*GAPDH
*B2M *SDHA *B2M
SDHA YWHAZ HMBS
UBC UBC TBP
HMBS TBP RP II
TBP RP II SDHA
RP II B2M YWHAZ
B
GROUPED CEREBELLUM + MEDIAL TEMPORAL GYRUS
AD + Controls PD + Controls DLB + Controls
*B2M/*GAPDH *RP II/*B2M *UBC/*GAPDH
*SDHA *UBC *B2M
*UBC *TBP HMBS
*HMBS SDHA RP II
RP II GAPDH TBP
YWHAZ HMBS SDHA
TBP YWHAZ YWHAZ
Candidate references genes were ranked in order of stability for each 
group, with the two most stable genes at the top and the least stable 
at the bottom. An * indicates the set of reference genes which should 
be employed for the normalization of RT qPCR data for each group as 
determined from analysis of the pairwise variation.BMC Molecular Biology 2008, 9:46 http://www.biomedcentral.com/1471-2199/9/46
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A summary of the gene stability results for each subject
grouping is presented in Table 3A &3B, with the optimum
number of genes for each (as indicated by geNorm analy-
sis) being indicated with asterisks. Some similarities in the
ranking of candidate gene stability were observed between
the medial temporal gyrus of each disease state with the
cerebellum of the same group.
The stability of the candidate reference genes was also
examined across a larger grouping that combined the cer-
ebellum and medial temporal gyrus of each subject group.
When considering genes for data normalization from cer-
ebellum and medial temporal gyrus together, of both con-
trol and AD subjects, the candidate reference genes were
ranked in order of stability from the most stable to the
least stable (Additional File 6A). Calculation of the pair-
wise variation for the inclusion of each additional gene
indicated five genes as the number of reference genes
required to reach the threshold of 0.15 (Additional File
7A). Therefore, employing B2M, GAPDH, SDHA, UBC
and HMBS as reference genes for data normalization
would be necessary in the medial temporal gyrus and cer-
ebellum of the control and AD subject group.
Similar analysis for the control and PD grouped subjects
showed a gradual decrease in pairwise variation to V6/7
(Additional File 7B), although the inclusion of four genes
produced a pairwise variation of 0.154, just over the
threshold, indicating that four genes may be sufficient.
Analysis of the pairwise variation in DLB and control
grouping demonstrated a V2/3 = 0.135; therefore although
the inclusion of a fourth gene was found to improve the
pairwise variation (Additional File 7C), the use of three
reference genes (UBC, GAPDH, B2M) for normalisation
of data in this group would be adequate.
As expected, due to the increased number of samples in
these analyses, the level of variation increased, and hence
additional reference genes would be required for accurate
data normalization. Five, four and three reference genes
were found to be the optimal number required for the cer-
ebellum and medial temporal gyrus of the controls and
AD subjects, controls and PD subjects, and controls and
DLB subject groupings respectively (Table 3B).
In order to substantiate the findings from the geNorm
analysis, our data was also analysed using an alternative
application, NormFinder [15]. In addition to estimating
the overall expression variation of the candidate reference
genes, NormFinder also estimates the variation between
sample subgroups. The reference gene stability results gen-
erated by NormFinder are presented in Additional File 8
for comparison.
Discussion
As far as we are aware, this is the first study of the expres-
sion stability of candidate reference genes in post mortem
brain tissue from individuals with AD, PD, DLB, and con-
trols using geNorm analysis. This study identified groups
of genes suitable for accurate normalization of RT qPCR
data in the sample subsets. An overlap in the most suita-
ble reference genes can be seen between disease states; for
example, GAPDH was one of the most stable genes in the
cerebellum of all disease states examined. This is in agree-
ment with the work of Grunblatt et al. who found GAPDH
to be suitable for RT qPCR data normalisation in the sub-
stantia nigra pars compacta of Parkinson's subjects [27].
B2M was found to be one of the most stable genes in the
cerebellum for the AD, DLB (with control) groups. How-
ever, B2M was found to be the least stable in the PD and
control cerebellum. This emphasises the fact that having a
gene that is stable in one disease state does not mean the
same gene will be stable in a different disease.
The top two most stable genes identified by Normfinder
were also in the set recommended by geNorm, for AD,
PD, and DLB temporal cortex (with controls), and PD,
and DLB cerebellum. In the AD and control cerebellum,
Normfinder identified UBC and SDHA as the top two sta-
ble genes, whereas geNorm identified YWAZ, GAPDH and
B2M. This may indicate that expression of all these genes
were stable enough to represent viable reference genes in
the study.
There are a number of limitations to the present study that
can be addressed in future work. One relates to the issue
of RNA quality, as degradation of RNA can introduce error
in this type of study, particularly if the extent of degrada-
tion varies between control and study groups [23]. This
can be a particular problem in post mortem brain tissue
obtained naturalistically. We attempted to maintain RNA
integrity by using samples that were snap frozen following
a short PMD, handling tissue on dry ice to avoid freeze-
thawing, and including RNase inhibitors during extrac-
tion. Despite this, sample RINs were not ideal in this
study, but importantly, they did not differ between con-
trol and disease groups. In addition, several practices were
adopted to minimise the effect which any RNA degrada-
tion might have had on RT-qPCR assays. In the RT reac-
tions, random nonomer primers were included in
addition to the oligo dT primer, ensuring RT reaction
priming at random sites along the RNA strand, in addition
to being primed from the polyA tail, and minimising the
possible influence of RNA degradation. A recent investiga-
tion of the effect of RNA integrity (using RIN) indicated
that while a value of 5 or above was desirable for RT-
qPCR, RINs (ranging from 1–10) did not affect PCR effi-
ciency, and did not correlate with normalised data [26].
The chances of an amplicon spanning a break in the RNABMC Molecular Biology 2008, 9:46 http://www.biomedcentral.com/1471-2199/9/46
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increase dramatically with increasing size, and the impor-
tance of using short amplicons is highlighted in this study,
which found that amplicons > 400 bp were strongly
dependent on RNA integrity, while shorter products (70 –
250 bp) were 'independent' of RNA quality [26]. A sepa-
rate study of post mortem brain RNA integrity and RT-
qPCR assay data revealed an effect when data was normal-
ised to β-actin (171 bp amplicon), and no effect when
using another reference gene, β-glucuronidase with a
shorter amplicon (81 bp) [23]. Our study used short
amplicons throughout, of 127 bp or less. The lack of cor-
relation observed between RIN and Q for any of the genes
analysed in the present study, in either cerebellar or
medial temporal gyrus tissue, indicates that these meas-
ures were successful.
We hypothesised that differential candidate reference
gene expression may be observed in regions with different
degrees of involvement in the neurodegenerative process.
Since the temporal cortex is one of the earliest affected
areas in AD, the increased variation of gene expression in
the medial temporal gyrus of the AD subjects relative to
the corresponding controls might have been expected (Fig
1E & F). Conversely, the cerebellum is thought to be one
of the least affected areas of the AD brain and one would
therefore expect it to display similar properties to that of
the cerebellum from control subjects. However, our data
shows a slight increase in the variation of gene expression
between the cerebellum of AD subjects and that of the
controls. This may be an indication that, although the cer-
ebellum appears relatively unaffected by AD, some cere-
bellar pathology is present as previously described in the
literature [28-30]. Interestingly, the observed range of
expression of the genes in both the cerebellum and the
medial temporal gyrus of the control subjects is generally
much smaller than the range of expression of the same
genes in the disease subjects. This observation again
strengthens the argument for the need to validate refer-
ence genes for use in any given disease state.
Conclusion
As proposed by Vandesompele et al. [17], we have identi-
fied several distinct sets of genes appropriate for RT qPCR
data normalization in AD, PD and DLB post mortem
brain tissue. Table 3A &3B indicate the appropriate refer-
ence genes from our panel for use in each disease state.
This study has provided further evidence that candidate
reference genes will not necessarily maintain their validity
across differing brain regions or disease states, and that
employing a single gene for data normalization would be
inadequate.
Methods
Reference Genes
Potential candidate reference genes were identified from a
search of the relevant literature, particularly relating to ref-
erence genes previously employed in neurodegenerative
diseases. As can be seen in Table 1, the genes included in
the study ranged from traditional, commonly used refer-
ence genes such as GAPDH to less well known genes such
as HMBS, spanning a range of cellular functions. In some
earlier studies of gene expression stability, ribosomal sub-
unit RNAs were excluded from the gene panels since only
oligo(dT) primers were employed in the RT [7]. Due to
large differences in the expression levels between refer-
ence genes and possible target genes, we elected to exclude
certain previously used genes, such as r18S, due their high
levels of expression. Such high abundance relative to a tar-
get can make the subtraction of baseline values in the RT
qPCR data analysis difficult [17]. However, since a modi-
fied RT protocol (described below) utilising both
oligo(dT) and random monomer primers was employed,
RP II was included.
β-actin has previously been employed as a reference gene
in gene expression studies in substantia nigra of PD brain
[27]. However, recent work by Barrachina et al. [23] indi-
cated that β-actin was more susceptible to the effects of
RNA degradation than other reference genes they exam-
ined, therefore we chose to exclude it.
Tissue Samples
Human post-mortem brain tissue was obtained via the
rapid autopsy program of The Netherlands Brain Bank
(NBB), (Netherlands Institute for Neuroscience, Amster-
dam, The Netherlands) which supplies post-mortem spec-
imens from clinically well documented and
neuropathologically confirmed cases. Autopsies are per-
formed on donors from whom written informed consent
has been obtained from either the donor or direct next of
kin. The work of the NBB abides by the Ethical code of
conduct approved by the ethics committee. Information is
available for all donors to allow matching for various
ante- and post-mortem factors. Ante-mortem information
includes age, sex, agonal state, date and time of death and
medication [31,32]. Post-mortem information includes
post-mortem delay (PMD), pH of cerebrospinal fluid
(CSF), and tissue storage time.
Tissue from the medial temporal gyrus and cerebellum
were obtained from 5 control subjects with no history of
neurological or psychiatric disorders and from 6 AD, 6
PD, and 6 DLB subjects. Tissue was dissected, snap frozen
under liquid nitrogen, and stored at -70°C. Details of
diagnosis, sex, age, Braak staging, PMD, and CSF pH for
the subjects are presented in Table 4.BMC Molecular Biology 2008, 9:46 http://www.biomedcentral.com/1471-2199/9/46
Page 8 of 11
(page number not for citation purposes)
Extraction of Total RNA and cDNA Synthesis
Care was taken to prevent RNA degradation by employing
good molecular biology practices. These included the use
of gloves at all times, the use of nuclease free molecular
biology grade water (Eppendorf) for all buffers, and the
cleaning of all working surfaces with RNase Away (Molec-
ular BioProducts) prior to working.
Tissue samples (~100 mg) were cut from the snap frozen
post-mortem samples on dry ice, transferred immediately
to QIAzol lysis reagent (Qiagen), which facilitates lysis of
fatty tissues and inhibit RNases, and then homogenised
using an Ultra-Turrax T25 homogeniser. Total RNA was
extracted using an RNeasy® Lipid Tissue Mini Kit (Qiagen),
which includes DNase treatment to degrade genomic
DNA. Total RNA in each sample was quantified using the
(fluorescent) RNA specific Ribogreen®  assay, which
employs an RNA standard curve (Molecular Probes, Invit-
rogen). Purified total RNA was heat denatured (2 min @
70°C). RNA integrity was determined using RNA 6000
Nano Labchips® in an Agilent 2100 Bioanalyzer following
the manufactures protocol. The concentration of RNA
obtained from the tissue samples varied from 0.19 – 1.16
μg/μl and was adjusted to 0.1 μg/μl using nuclease-free
water. 2 μg RNA was used in each 20 μl reverse transcrip-
tion (RT) reaction. The RT reactions were performed with
an Omniscript®  Reverse Transcription Kit (Qiagen)
according to the manufacturers protocol in which random
nonomer primers at a final concentration of 10 μM were
added to the master mix, in addition to the oligo dT prim-
ers.
Real-Time PCR
RT qPCR reactions were carried out for all genes of interest
in each sample using cDNA specific TaqMan®  Gene
Expression Assays on an ABI 7500 Real-Time PCR System
Table 4: Main clinical and neuropathological data for subjects
Diagnosis Sex Age Braak Stage PM Delay (min) CSF pH
AD f 81 4 193 6.54
f 85 4 220 6.59
f 77 5 215 6.67
m9 5 5 1 8 5 6 . 4
m 58 6 385 6.42
f 87 6 300 6.66
Mean ± S.D. 80.50 ± 11.49 249.67 ± 71.09 6.55 ± 0.11
PD m 75 n/a 255 6.42
f 83 3 290 6.76
f 80 3 480 6.85
m 82 3 425 7.64
f 80 3 255 6.50
f 84 1 370 6.50
Mean ± S.D. 80.67 ± 2.92 345.83 ± 86.09 6.78 ± 0.41
DLB f7 9 1 2 0 0 6 . 4
m 74 1 255 6.12
m 81 2 345 6.63
m8 6 2 4 7 2 n / a
f 79 3 235 6.72
m9 5 2 2 7 0 6 . 6
Mean ± S.D. 82.33 ± 6.67 296.17 ± 90.07 6.49 ± 0.21
Controls f 69 1 375 6.59
f 72 1 405 6.52
m 79 1 320 6.72
m 83 1 275 6.49
f8 8 2 3 4 0 n / a
Mean ± S.D. 78.20 ± 6.97 343.00 ± 44.79 6.58 ± 0.09
Unpaired t-tests were used to verify that the AD, PD, DLB and control groups were matched for age, post-mortem (PM) delay and pH of CSF.BMC Molecular Biology 2008, 9:46 http://www.biomedcentral.com/1471-2199/9/46
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(Applied Biosystems). In each 25 μl TaqMan® reaction, 10
μl cDNA (corresponding to the cDNA reverse transcribed
from approximately 10 ng RNA) was mixed with 1.25 μl
TaqMan® Gene Expression Assay and 12.5 μl TaqMan®
Universal PCR Master Mix (Applied Biosystems) and 1.25
μl H20. This allowed for the consistent use of standardised
thermal cycling conditions: 95°C for 10 min, followed by
40 cycles of 95°C for 15 sec and 60°C for 1 min (note that
the 50°C for 2 min step was omitted since AmpErase
UNG was not included in the reaction mixture) which
were found to give efficiencies > 92% (see below). Unless
otherwise stated, all RT qPCR reactions were run in dupli-
cate.
No template control reactions were included in each assay
run. The Taqman® Gene Expression assays employed are
cDNA specific assays, and are therefore unable to detect
genomic DNA if present.
PCR Efficiency
A 10-fold dilution series was created from a random pool
of cDNA from our sample group (including age matched
controls, AD, PD and DLB patient samples) ranging from
×10 dilution to ×100000 dilution. Triplicate RT qPCR
reactions were carried out as described above for each
gene at each dilution. Mean cycle threshold (Ct) values for
each dilution were plotted against the log10 of the cDNA
input for each gene to generate efficiency plots. The reac-
tion efficiency for each gene assay was calculated using the
following equation: E = 10(-1/slope) where E is the reaction
efficiency and 'slope' is the slope of the line generated in
the efficiency plots.
Data Analysis
The mean Ct values of the replicates for each sample were
transformed into raw, non-normalised quantities (Q)
using the comparative ΔCt method by the equation Q =
EΔCt where E is the reaction efficiency for each gene assay
in question and ΔCt = min Ct – sample Ct, where min Ct is
the lowest Ct value over a range of samples for a given
assay, and sample Ct is the Ct value of the sample being
transformed. The expression data was analysed using the
geNorm algorithm [33] which determines a reference
gene stability factor (M), defined as the average pairwise
variation of a particular gene compared with all of the
other candidate reference genes [17]. Hence, a lower value
of M indicates higher stability of the reference gene.
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tion efficiency and 'slope' is the slope of the line generated in the efficiency 
plots.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
2199-9-46-S1.doc]
Additional file 2
Stability of candidate reference genes in medial temporal gyrus. 
Expression stability plot showing the average expression stability (M) for 
the remaining genes following the sequential elimination of the least sta-
ble gene at each round in the medial temporal gyrus of control and PD 
subjects (A), and control and DLB subjects (B). Least stable (left) and the 
two most stable (right).
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Additional file 3
Pairwise variation of the candidate reference genes in medial tempo-
ral gyrus. Pairwise variation analysis to determine the optimal number of 
reference genes for use in RT qPCR data normalization from cerebellum 
of control and PD subjects (A), and control and DLB subjects (B). To 
determine the optimal number of genes required for geometric mean nor-
malization, geNorm calculates the pairwise variation (Vn/Vn+1) between 
sequential normalization factors (NF) (NFn and NFn+1). A large varia-
tion indicates that the gene included at that stage has a significant effect 
and should therefore be included for normalization.
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Additional file 4
Stability of candidate reference genes in cerebellum. Expression stabil-
ity plot showing the average expression stability (M) for the remaining 
genes following the sequential elimination of the least stable gene at each 
round in cerebellum of control and AD subjects (A), control and PD sub-
jects (B), and control and DLB subjects (C). Least stable (left) and the 
two most stable (right).
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